ZVSA — Zyversa Therapeutics Income Statement
0.000.00%
- $3.26m
- $1.23m
- 18
- 52
- 15
- 18
Annual income statement for Zyversa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 11.8 | 7.49 | 13.8 | 108 |
Operating Profit | -11.8 | -7.49 | -13.8 | -108 |
Total Net Non Operating Interest Income / Expense | ||||
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -12.7 | -8.08 | -14.9 | -108 |
Provision for Income Taxes | ||||
Net Income After Taxes | -12.7 | -8.08 | -14.1 | -98.3 |
Net Income Before Extraordinary Items | ||||
Net Income | -12.7 | -8.08 | -14.1 | -98.3 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -12.7 | -8.08 | -24.1 | -106 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -482 | -315 | -917 | -467 |
Dividends per Share |